Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS protein.

The circumsporozoite (CS) protein is a major candidate vaccine antigen for the sporozoite stage of malaria. Both cytotoxic T cells (CTL) and antibody specific for the CS protein are thought to be important in protection. By examining the immune response in mice and humans we have shown that genes mapping to the major histocompatibility complex (MHC) are important for immune responsiveness. F1 mice between high antibody responders and low antibody responders are high antibody responders, suggesting that in this model immune suppressor genes do not control the immune response. Using synthetic peptides to map epitopes for CTL and helper T cells (which are important for the antibody response) we have shown that the T-cell epitopes are located in the polymorphic region of the protein, and we hypothesize that T cells have indeed selected the variation observed in the CS protein. The success of subunit vaccines will depend on the pattern of variation in different geographical locations, the ability to construct multivalent vaccines containing different variant epitopes from this protein, and on the existence of other sporozoite and liver-stage proteins involved in protection.

[1]  J. Berzofsky,et al.  Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. , 1989, Journal of immunology.

[2]  A. Trzeciak,et al.  A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules , 1988, Nature.

[3]  J. Berzofsky,et al.  Human and murine CD4 T cell epitopes map to the same region of the malaria circumsporozoite protein: limited immunogenicity of sporozoites and circumsporozoite protein. , 1988, Molecular biology & medicine.

[4]  B. Moss,et al.  Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of nonresponder MHC class I alleles , 1988, The Journal of experimental medicine.

[5]  J. Adams,et al.  Limited immunological recognition of critical malaria vaccine candidate antigens. , 1988, Science.

[6]  T. McCutchan,et al.  Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. , 1988, Journal of immunology.

[7]  J. Berzofsky,et al.  Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum , 1988, Nature.

[8]  J. Ou,et al.  Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. , 1988, Science.

[9]  J. Berzofsky,et al.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Taylor,et al.  A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.

[11]  V. Nussenzweig,et al.  γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.

[12]  S. Hoffman,et al.  Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. , 1987, Science.

[13]  C. DeLisi,et al.  Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design , 1987, Immunological reviews.

[14]  Myron M. Levine,et al.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.

[15]  S. Hoffman,et al.  SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE , 1987, The Lancet.

[16]  H. Margalit,et al.  Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. , 1987, Science.

[17]  P. Lambert,et al.  The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. , 1986, Journal of immunology.

[18]  J. Berzofsky,et al.  Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine , 1986, The Journal of experimental medicine.

[19]  J. F. Young,et al.  Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. , 1985, Science.

[20]  V. Nussenzweig,et al.  Development of sporozoite vaccines. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[21]  V. Nussenzweig,et al.  Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection , 1980, The Journal of experimental medicine.

[22]  R. Tigelaar,et al.  Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice. , 1977, Journal of immunology.

[23]  J. Vanderberg,et al.  Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.

[24]  L. Miller,et al.  The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation. , 1988, Immunology today.

[25]  M. Good,et al.  CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Sell,et al.  Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. , 1979, Bulletin of the World Health Organization.